chartexchange

Lantern Pharma secures Taiwan clearances for Phase II NSCLC study

Clinical Trials Arena | Oct 8, 2026 6:05 AM EDT

Lantern Pharma has secured regulatory and IRB clearances in Taiwan to initiate Part 2 of its Phase II HARMONIC clinical trial of LP-300 in combination with carboplatin and pemetrexed in never-smokers with advanced NSCLC.
The post Lantern Pharma secures Taiwan clearances for Phase II NSCLC study appeared first on Clinical Trials Arena .

Read original article